Filing Flows › Immunocore Holdings (IMCR) › R&D spending
Immunocore Holdings (IMCR) R&D spending by quarter
Immunocore Holdings' R&D spending was $74.7M in Q3 2026 (third quarter 2026), +1% from Q2 2026. Over the last 7 quarters it ranged from $56.5M (Q1 2025) to $78.8M (Q4 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $74.7M | +1% | +6% |
| Q2 2026 | $73.9M | +21% | +7% |
| Q1 2026 | $61.1M | -22% | +8% |
| Q4 2025 | $78.8M | +12% | — |
| Q3 2025 | $70.6M | +2% | — |
| Q2 2025 | $69.0M | +22% | — |
| Q1 2025 | $56.5M | — | — |
Q3 2026 at a glance
Immunocore Holdings, Q3 2026: revenue $102M (-1% year over year), operating margin -13.3%, net loss $14.2M, operating cash flow $20.1M. The chart follows the revenue to costs, profit and cash.
Questions
What is Immunocore Holdings' R&D spending?
Immunocore Holdings' R&D spending was $74.7M in Q3 2026 (third quarter 2026), +1% from Q2 2026.
How has Immunocore Holdings' R&D spending changed?
Over the last 7 quarters it ranged from $56.5M (Q1 2025) to $78.8M (Q4 2025).